Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

14:14 EST 24th January 2017 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

Some Increased Bleeding Risk Seen With Blood Thinner Xarelto Vs. Pradaxa

MONDAY, Oct. 3, 2016 -- The blood thinner Xarelto may pose a slightly greater risk of serious bleeding than Pradaxa in patients with the abnormal heartbeat known as atrial fibrillation, new research s...

Venous Thromboembolism therapeutics market set to hit $3.7 bn by 2025

Biospectrum Pradaxa, Xarelto, and Eliquis, which are all currently available, will see improved uptake over the forecas...

Portola's anticoagulant antidote gets EU review

Portola has said European regulators are to review its anticoagulantĀ antidote, IndexXa (andexanet alfa), just days after the US regulator rejected the drug. California-based Portola said the Europea...

BRIEF-Bayer comments on the article in "Handelsblatt" on Xarelto

* Believes statements published in 'Handelsblatt' on Nov. 9. about Xarelto are misleading

Janssen: Less Bleeding with Xarelto in Some Patients

NewsPhase 3b study shows significantly less bleeding with Xarelto (rivaroxaban) compared to Warfarin in people with non-valvular atrial fibrillation following percutaneous coronary intervention with s...

FDA clears Xarelto blood thinner despite faulty trial device

The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial fibrillation after s...

U.S. FDA clears Xarelto blood thinner despite faulty trial device

Oct 11 (Reuters) - The U.S. Food and Drug Administration on Tuesday said it has determined the widely-used blood thinner Xarelto to be safe and effective for patients with the heart condition atrial f...

Boehringer Ingelheim Presents Real-world Analysis of Pradaxa Users

NewsPharmaceutical company Boehringer Ingelheim Pharmaceuticals Inc., presented two studies at the American Society of Hematology Annual Meeting in San Diego, which showed patients who were newly diag...

Matching PubMed Articles

Praxbind Available as Antidote to Bleeding from Pradaxa.

Caution When Prescribing Xarelto to First-Time Patients.

Perioperative Management of Direct Oral Anticoagulants (DOACs): A Systemic Review.

Direct oral anticoagulants (DOACs) are in wide use among patients requiring both short- and long-term anticoagulation, mainly due to their ease of use and the lack of monitoring requirements. With gro...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement